Mitochondria-Targeting Particles

References

• Wang B , GallifordCV, LowPS. Guiding principles in the design of ligand-targeted nanomedicines. Nanomedicine (Lond.)9 (2), 313–330 (2014).
   PubMed Web of Science ®Google Scholar
• Martinho N , DamgeC, ReisC. Recent advances in drug delivery systems. J. Biomater. Nanobiotechnol.2 (5A), 510–526 (2011).
   Google Scholar
• Weissig V , BoddapatiSV, JabrL, D'SouzaGG. Mitochondria-specific nanotechnology. Nanomedicine (Lond.)2 (3), 275–285 (2007).
   PubMed Web of Science ®Google Scholar
• Murphy MP , SmithRA. Drug delivery to mitochondria: the key to mitochondrial medicine. Adv. Drug Deliv. Rev.41 (2), 235–250 (2000).
   PubMed Web of Science ®Google Scholar
• Bayeva M , GheorghiadeM, ArdehaliH. Mitochondria as a therapeutic target in heart failure. J. Am. Coll. Cardiol.61 (6), 599–610 (2013).
   PubMed Web of Science ®Google Scholar
• Moreira PI , ZhuX, WangXet al. Mitochondria: atherapeutic target in neurodegeneration. Biochim. Biophys. Acta1802 (1), 212–220 (2010).
   PubMed Web of Science ®Google Scholar
• Taylor RW , TurnbullDM. Mitochondrial DNA mutations in human disease. Nat. Rev. Genet.6 (5), 389–402 (2005).
   PubMed Web of Science ®Google Scholar
• Walters AM , PorterGAJr, BrookesPS. Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ. Res.111 (9), 1222–1236 (2012).
   PubMed Web of Science ®Google Scholar
• Joiner ML , KovalOM, LiJet al. CaMKII determines mitochondrial stress responses in heart. Nature491 (7423), 269–273 (2012).
   PubMed Web of Science ®Google Scholar
• Pradelli LA , BeneteauM, RicciJE. Mitochondrial control of caspase-dependent and -independent cell death. Cell Mol. Life Sci.67 (10), 1589–1597 (2010).
   PubMed Web of Science ®Google Scholar
• Szeto HH , SchillerPW. Novel therapies targeting inner mitochondrial membrane – from discovery to clinical development. Pharm. Res.28 (11), 2669–2679 (2011).
   PubMed Web of Science ®Google Scholar
• Kinnally KW , PeixotoPM, RyuS-Y, DejeanLM. Is mPTP the gatekeeper for necrosis, apoptosis, or both?Biochim. Biophys. Acta1813 (4), 616–622 (2011).
   PubMed Web of Science ®Google Scholar
• Dumont M , LinMT, BealMF. Mitochondria and antioxidant targeted therapeutic strategies for Alzheimer's disease. J. Alzheimers Dis.20 (Suppl. 2), S633–S643 (2010).
   PubMedGoogle Scholar
• Jin H , KanthasamyA, GhoshA, AnantharamV, KalyanaramanB, KanthasamyAG. Mitochondria-targeted antioxidants for treatment of Parkinson's disease: preclinical and clinical outcomes. Biochim. Biophys. Acta1842 (8), 1282–1294 (2013).
   PubMed Web of Science ®Google Scholar
• Reddy PH . Mitochondrial medicine for aging and neurodegenerative diseases. Neuromolecular Med.10 (4), 291–315 (2008).
   PubMed Web of Science ®Google Scholar
• Moreira PI , ZhuX, WangXet al. Mitochondria: a therapeutic target in neurodegeneration. Biochim. Biophys. Acta1802 (1), 212–220 (2010).
   PubMed Web of Science ®Google Scholar
• Uttara B , SinghAV, ZamboniP, MahajanRT. Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr. Neuropharmacol.7 (1), 65–74 (2009).
   PubMed Web of Science ®Google Scholar
• Rohlena J , DongLF, RalphSJ, NeuzilJ. Anticancer drugs targeting the mitochondrial electron transport chain. Antioxid. Redox Signal.15 (12), 2951–2974 (2011).
   PubMed Web of Science ®Google Scholar
• Ferrin G , LinaresCI, MuntaneJ. Mitochondrial drug targets in cell death and cancer. Curr. Pharm. Des.17 (20), 2002–2016 (2011).
   PubMed Web of Science ®Google Scholar
• Wang F , OgasawaraMA, HuangP. Small mitochondria-targeting molecules as anti-cancer agents. Mol. Aspects Med.31 (1), 75–92 (2010).
   PubMed Web of Science ®Google Scholar
• Marullo R , WernerE, DegtyarevaNet al. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. PLoS One8 (11), e81162 (2013).
   PubMed Web of Science ®Google Scholar
• Sakhrani NM , PadhH. Organelle targeting: third level of drug targeting. Drug Des. Devel. Ther.7, 585–599 (2013).
   PubMed Web of Science ®Google Scholar
• Birk AV , LiuS, SoongYet al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. J. Am. Soc. Nephrol.24 (8), 1250–1261 (2013).
   PubMed Web of Science ®Google Scholar
• Chakrabarti AK , FeeneyK, AbuegCet al. Rationale and design of the EMBRACE STEMI study: a Phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. Am. Heart J.165 (4), 509–514.e7 (2013).
   PubMed Web of Science ®Google Scholar
• Smith RA , MerphyMP. Mitochondria-targeted antioxidants as therapies. Discov. Med.11 (57), 106–114 (2011).
   PubMed Web of Science ®Google Scholar
• Smith RA , PorteousCM, GaneAM, MurphyMP. Delivery of bioactive molecules to mitochondria in vivo. Proc. Natl Acad. Sci. USA100 (9), 5407–5412 (2003).
   PubMed Web of Science ®Google Scholar
• Mao P , ManczakM, ShirendebUP, ReddyPH. MitoQ, a mitochondria-targeted antioxidant, delays disease progression and alleviates pathogenesis in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Biochim. Biophys. Acta1832 (12), 2322–2331 (2013).
   PubMed Web of Science ®Google Scholar
• Miquel E , CassinaA, Martinez-PalmaLet al. Neuroprotective effects of the mitochondria-targeted antioxidant MitoQ in a model of inherited amyotrophic lateral sclerosis. Free Radic. Biol. Med.70, 204–213 (2014).
   PubMed Web of Science ®Google Scholar
• Smith RA , MurphyMP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Ann. NY Acad. Sci.1201, 96–103 (2010).
   PubMed Web of Science ®Google Scholar
• Chamberlain GR , TulumelloDV, KelleySO. Targeted delivery of doxorubicin to mitochondria. ACS Chem. Biol.8 (7), 1389–1395 (2013).
   PubMed Web of Science ®Google Scholar
• Bangham AD , StandishMM, WatkinsJC. Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol.13 (1), 238–252 (1965).
   PubMed Web of Science ®Google Scholar
• Chang HI , YehMK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int. J. Nanomedicine7, 49–60 (2012).
   PubMed Web of Science ®Google Scholar
• Allen TM , CullisPR. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev.65 (1), 36–48 (2013).
   PubMed Web of Science ®Google Scholar
• Weissig V , LaschJ, ErdosG, MeyerHW, RoweTC, HughesJ. DQAsomes: a novel potential drug and gene delivery system made from Dequalinium. Pharm. Res.15 (2), 334–337 (1998).
   PubMed Web of Science ®Google Scholar
• Weissig V , LizanoC, TorchilinVP. Selective DNA release from DQAsome/DNA complexes at mitochondria-like membranes. Drug Deliv.7 (1), 1–5 (2000).
   PubMed Web of Science ®Google Scholar
• Weissig V , D'souzaGG, TorchilinVP. DQAsome/DNA complexes release DNA upon contact with isolated mouse liver mitochondria. J Control. Release75 (3), 401–408 (2001).
   PubMed Web of Science ®Google Scholar
• D'souza GG , RammohanR, ChengSM, TorchilinVP, WeissigV. DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J Control. Release92 (1–2), 189–197 (2003).
   PubMed Web of Science ®Google Scholar
• Andre N , CarreM, BrasseurGet al. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett.532 (1–2), 256–260 (2002).
   PubMed Web of Science ®Google Scholar
• D'souza GG , ChengSM, BoddapatiSV, HorobinRW, WeissigV. Nanocarrier-assisted sub-cellular targeting to the site of mitochondria improves the pro-apoptotic activity of paclitaxel. J. Drug Target.16 (7), 578–585 (2008).
   PubMed Web of Science ®Google Scholar
• Men Y , WangXX, LiRJet al. The efficacy of mitochondrial targeting antiresistant epirubicin liposomes in treating resistant leukemia in animals. Int. J. Nanomedicine6, 3125–3137 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang L , YaoHJ, YuYet al. Mitochondrial targeting liposomes incorporating daunorubicin and quinacrine for treatment of relapsed breast cancer arising from cancer stem cells. Biomaterials33 (2), 565–582 (2012).
   PubMed Web of Science ®Google Scholar
• Yu Y , WangZH, ZhangLet al. Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma. Biomaterials33 (6), 1808–1820 (2012).
   PubMed Web of Science ®Google Scholar
• Collnot EM , BaldesC, SchaeferUF, EdgarKJ, WempeMF, LehrCM. Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol. Pharm.7 (3), 642–651 (2010).
   PubMed Web of Science ®Google Scholar
• Wang XX , LiYB, YaoHJet al. The use of mitochondrial targeting resveratrol liposomes modified with a dequalinium polyethylene glycol-distearoylphosphatidyl ethanolamine conjugate to induce apoptosis in resistant lung cancer cells. Biomaterials32 (24), 5673–5687 (2011).
   PubMed Web of Science ®Google Scholar
• Li N , ZhangCX, WangXXet al. Development of targeting lonidamine liposomes that circumvent drug-resistant cancer by acting on mitochondrial signaling pathways. Biomaterials34 (13), 3366–3380 (2013).
   PubMed Web of Science ®Google Scholar
• Carter LG , D'orazioJA, PearsonKJ. Resveratrol and cancer: a focus on in vivo evidence. Endocr. Relat. Cancer21 (3), R209–R225 (2014).
   PubMed Web of Science ®Google Scholar
• Pan Y , ZhaoW, WangJ, LiuQ, YangG, LiJ. [Establishment of a multidrug resistance cell line A549/cDDP of human lung adenocarcinoma and expression analysis of multidrug resistance-associated genes.]. Zhongguo Fei Ai Za Zhi12 (3), 187–192 (2009).
   PubMedGoogle Scholar
• Mullen TD , ObeidLM. Ceramide and apoptosis: exploring the enigmatic connections between sphingolipid metabolism and programmed cell death. Anticancer Agents Med. Chem.12 (4), 340–363 (2012).
   PubMed Web of Science ®Google Scholar
• Boddapati SV , D'souzaGG, ErdoganS, TorchilinVP, WeissigV. Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett.8 (8), 2559–2563 (2008).
   PubMed Web of Science ®Google Scholar
• Solomon MA , ShahAA, D'SouzaGG. In vitro assessment of the utility of stearyl triphenyl phosphonium modified liposomes in overcoming the resistance of ovarian carcinoma Ovcar-3 cells to paclitaxel. Mitochondrion13 (5), 464–472 (2013).
   PubMed Web of Science ®Google Scholar
• Biswas S , DodwadkarNS, DeshpandePP, TorchilinVP. Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium–PEG–PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J. Control. Release159 (3), 393–402 (2012).
   PubMed Web of Science ®Google Scholar
• Patel NR , HatziantoniouS, GeorgopoulosAet al. Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol. J. Liposome Res.20 (3), 244–249 (2010).
   PubMed Web of Science ®Google Scholar
• Zhou J , ZhaoWY, MaXet al. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials34 (14), 3626–3638 (2013).
   PubMed Web of Science ®Google Scholar
• Wagle MA , MartinvilleLE, D'SouzaGG. The utility of an isolated mitochondrial fraction in the preparation of liposomes for the specific delivery of bioactives to mitochondria in live mammalian cells. Pharm. Res.28 (11), 2790–2796 (2011).
   PubMed Web of Science ®Google Scholar
• Yamada Y , AkitaH, KamiyaHet al. MITO-Porter: aliposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion. Biochim. Biophys. Acta1778 (2), 423–432 (2008).
   PubMed Web of Science ®Google Scholar
• Yasuzaki Y , YamadaY, HarashimaH. Mitochondrial matrix delivery using MITO-Porter, a liposome-based carrier that specifies fusion with mitochondrial membranes. Biochem. Biophys. Res. Commun.397 (2), 181–186 (2010).
   PubMed Web of Science ®Google Scholar
• Kawamura E , YamadaY, HarashimaH. Mitochondrial targeting functional peptides as potential devices for the mitochondrial delivery of a DF-MITO-Porter. Mitochondrion13 (6), 610–614 (2013).
   PubMed Web of Science ®Google Scholar
• Yamada Y , FurukawaR, YasuzakiY, HarashimaH. Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery. Mol. Ther.19 (8), 1449–1456 (2011).
   PubMed Web of Science ®Google Scholar
• Khalil IA , KogureK, FutakiS, HarashimaH. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J. Biol. Chem.281 (6), 3544–3551 (2006).
   PubMed Web of Science ®Google Scholar
• Yamada Y , HarashimaH. Delivery of bioactive molecules to the mitochondrial genome using a membrane-fusing, liposome-based carrier, DF-MITO-Porter. Biomaterials33 (5), 1589–1595 (2012).
   PubMed Web of Science ®Google Scholar
• Lu JM , WangX, Marin-MullerCet al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev. Mol. Diagn.9 (4), 325–341 (2009).
   PubMed Web of Science ®Google Scholar
• Vilar G , Tulla-PucheJ, AlbericioF. Polymers and drug delivery systems. Curr. Drug Deliv.9 (4), 367–394 (2012).
   PubMed Web of Science ®Google Scholar
• Astete CE , SabliovCM. Synthesis and characterization of PLGA nanoparticles. J. Biomater. Sci. Polym. Ed.17 (3), 247–289 (2006).
   PubMed Web of Science ®Google Scholar
• Marrache S , DharS. Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeutics. Proc. Natl Acad. Sci. USA109 (40), 16288–16293 (2012).
   PubMed Web of Science ®Google Scholar
• Mishra S , PalaniveluK. The effect of curcumin (turmeric) on Alzheimer's disease: an overview. Ann. Indian Acad. Neurol.11 (1), 13–19 (2008).
   PubMed Web of Science ®Google Scholar
• Potter PE . Curcumin: a natural substance with potential efficacy in Alzheimer's disease. J. Exp. Pharmacol.5, 9 (2013).
   Google Scholar
• Grundlingh J , DarganPI, El-ZanfalyM, WoodDM. 2,4-dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of death. J. Med. Toxicol.7 (3), 205–212 (2011).
   PubMedGoogle Scholar
• Rothblat GH , PhillipsMC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr. Opin. Lipidol.21 (3), 229–238 (2010).
   PubMed Web of Science ®Google Scholar
• Seimon T , TabasI. Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J. Lipid Res.50 (Suppl.), S382–S387 (2009).
   PubMedGoogle Scholar
• Karaflou M , LambrinoudakiI, ChristodoulakosG. Apoptosis in atherosclerosis: a mini-review. Mini Rev. Med. Chem.8 (9), 912–918 (2008).
   PubMed Web of Science ®Google Scholar
• Marrache S , DharS. Biodegradable synthetic high-density lipoprotein nanoparticles for atherosclerosis. Proc. Natl Acad. Sci. USA110 (23), 9445–9450 (2013).
   PubMed Web of Science ®Google Scholar
• Marrache S , TundupS, HarnDA, DharS. Ex vivo programming of dendritic cells by mitochondria-targeted nanoparticles to produce interferon-gamma for cancer immunotherapy. ACS Nano7 (8), 7392–7402 (2013).
   PubMed Web of Science ®Google Scholar
• Dykman LA , KhlebtsovNG. Gold nanoparticles in biology and medicine: recent advances and prospects. Acta Naturae3 (2), 34–55 (2011).
   PubMed Web of Science ®Google Scholar
• Ong C , LimJZ, NgCT, LiJJ, YungLY, BayBH. Silver nanoparticles in cancer: therapeutic efficacy and toxicity. Curr. Med. Chem.20 (6), 772–781 (2013).
   PubMed Web of Science ®Google Scholar
• Dreaden EC , AustinLA, MackeyMA, El-SayedMA. Size matters: gold nanoparticles in targeted cancer drug delivery. Ther. Deliv.3 (4), 457–478 (2012).
   PubMedGoogle Scholar
• Ma X , WangX, ZhouM, FeiH. A mitochondria-targeting gold-peptide nanoassembly for enhanced cancer-cell killing. Adv. Healthc. Mater.2 (12), 1638–1643 (2013).
   PubMed Web of Science ®Google Scholar
• Law B , QuintiL, ChoiY, WeisslederR, TungCH. A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity. Mol. Cancer Ther.5 (8), 1944–1949 (2006).
   PubMed Web of Science ®Google Scholar
• McCully JD , LevitskyS. The mitochondrial K(ATP) channel and cardioprotection. Ann. Thorac. Surg.75 (2), S667–S673 (2003).
   PubMed Web of Science ®Google Scholar
• Spivak MY , BubnovRV, YemetsIM, LazarenkoLM, TymoshokNO, UlbergZR. Development and testing of gold nanoparticles for drug delivery and treatment of heart failure: a theranostic potential for PPP cardiology. EPMA J.4 (1), 20 (2013).
   PubMedGoogle Scholar
• Paunesku T , VogtS, LaiBet al. Intracellular distribution of TiO2-DNA oligonucleotide nanoconjugates directed to nucleolus and mitochondria indicates sequence specificity. Nano Lett.7 (3), 596–601 (2007).
   PubMed Web of Science ®Google Scholar
• Wang Y , ZiXY, SuJet al. Cuprous oxide nanoparticles selectively induce apoptosis of tumor cells. Int. J. Nanomedicine7, 2641–2652 (2012).
   PubMed Web of Science ®Google Scholar
• Wang Y , YangF, ZhangHXet al. Cuprous oxide nanoparticles inhibit the growth and metastasis of melanoma by targeting mitochondria. Cell Death Dis.4, e783 (2013).
   PubMed Web of Science ®Google Scholar
• Ragg R , NatalioF, TahirMNet al. Molybdenum trioxide nanoparticles with intrinsic sulfite oxidase activity. ACS Nano8 (5), 5182–5189 (2014).
   PubMed Web of Science ®Google Scholar